Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27880615 | 0.98 | ALDH1A1 (0.56) | ALDH1A1MAPK1TDP1NAPRTHTT | |
| SCHEMBL29058267 | 0.87 | HDAC1 (0.55) | ALDH1A1MAPK1TDP1NAPRTHTT | |
| SCHEMBL6997673 | 0.82 | HTT (0.67) | ALDH1A1MAPK1TDP1NAPRTHTT | |
| SCHEMBL6997670 | 0.82 | HTT (0.67) | ALDH1A1MAPK1TDP1NAPRTHTT | |
| SCHEMBL222221 | 0.81 | ALDH1A1 (0.74) | ALDH1A1MAPK1TDP1HTTMEN1 | |
| Water SCHEMBL11592745 | 0.78 | ALDH1A1 (0.70) | ALDH1A1MAPK1TDP1HTTMEN1 | |
| Water SCHEMBL11592742 | 0.78 | ALDH1A1 (0.70) | ALDH1A1MAPK1TDP1HTTMEN1 | |
| SCHEMBL7811738 | 0.78 | AKT1 (0.60) | ALDH1A1MAPK1TDP1NAPRTHTT | |
| SCHEMBL27684753 | 0.78 | HTT (0.57) | ALDH1A1MAPK1NAPRTHTTMEN1 | |
| SCHEMBL4828448 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPK1NAPRTHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106029649-B | Ethynyl derivatives | 豪夫迈·罗氏有限公司 | 2019-02-12 | — | — | CN | claimed |
| CN-107207481-A | It is used as the derovatives of 3 (4 ethynyl phenyl) hexahydropyrimidine 2,4 of MGLUR4 conditioning agent | 豪夫迈·罗氏有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-106029649-A | Ethynyl derivatives | 豪夫迈·罗氏有限公司 | 2016-10-12 | — | — | CN | claimed |
| CN-1201789-A | Pyridine-3,4-diketone derivatives and their preparation and medicinal uses | UNIV ZHONGSHAN (CN) | 1998-12-16 | — | — | CN | claimed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| CN-116940555-A | Substituted pyridine-2, 4-dione derivatives | 深圳市康哲药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116940555-A | Substituted pyridine-2, 4-dione derivatives | 深圳市康哲药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| CN-1412181-A | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| CN-1201789-A | Pyridine-3,4-diketone derivatives and their preparation and medicinal uses | UNIV ZHONGSHAN (CN) | 1998-12-16 | — | — | CN | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| CN-1022325-C | Azolidinedione derovatives | PFIZER (US) | 1993-10-06 | — | — | CN | disclosed |
| CN-1031702-A | AZOLIDINEDIONE DEROVATIVES | PFIZER (US) | 1989-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | ALDH1A1 1721/4885MAPK1 3986/4885TDP1 288/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | ALDH1A1 1721/4885MAPK1 3986/4885TDP1 288/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | ALDH1A1 1721/4885MAPK1 3986/4885TDP1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.